| XLS |
|
|
|
|
|
|
|
€ million |
Q2 – 2013 |
Q2 – 2012 |
Jan.–June 2013 |
Jan.–June 2012 |
|
Profit after tax |
316.1 |
–60.5 |
585.1 |
114.6 |
|
Items of other comprehensive income that will not be reclassified to the income statement in subsequent periods: |
|
|
|
|
|
Remeasurement of the net defined benefit liability |
|
|
|
|
|
Changes in remeasurement |
44.2 |
–9.8 |
–43.6 |
–9.8 |
|
Deferred taxes |
–7.9 |
–1.9 |
6.8 |
–1.9 |
|
Changes recognized in equity |
36.3 |
–11.7 |
–36.8 |
–11.7 |
|
|
36.3 |
–11.7 |
–36.8 |
–11.7 |
|
Items of other comprehensive income that may be reclassified to the income statement in subsequent periods: |
|
|
|
|
|
Available-for-sale financial assets |
|
|
|
|
|
Fair value adjustments |
0.1 |
0.1 |
0.8 |
0.1 |
|
Reclassification to income statement |
– |
– |
– |
– |
|
Deferred taxes |
–0.1 |
– |
–0.5 |
– |
|
Changes recognized in equity |
– |
0.1 |
0.3 |
0.1 |
|
Derivative financial instruments |
|
|
|
|
|
Fair value adjustments |
65.1 |
–76.6 |
43.7 |
–51.0 |
|
Reclassification to income statement |
–1.8 |
12.3 |
–4.9 |
54.3 |
|
Deferred taxes |
–14.7 |
11.3 |
–7.2 |
1.2 |
|
Changes recognized in equity |
48.6 |
–53.0 |
31.6 |
4.5 |
|
Exchange differences on translating foreign operations |
|
|
|
|
|
Changes taken directly to equity |
–98.3 |
61.4 |
–77.3 |
42.0 |
|
Reclassification to income statement |
–7.6 |
– |
–7.6 |
– |
|
Changes recognized in equity |
–105.9 |
61.4 |
–84.9 |
42.0 |
|
|
–57.3 |
8.5 |
–53.1 |
46.6 |
|
Other comprehensive income |
–21.0 |
–3.2 |
–89.9 |
34.9 |
|
Comprehensive income |
295.1 |
–63.8 |
495.2 |
149.5 |
|
of which attributable to Merck KGaA shareholders |
299.7 |
–65.5 |
495.0 |
145.5 |
|
of which attributable to non-controlling interest |
–4.6 |
1.7 |
0.2 |
4.0 |
back
